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WHAT IS KNOWN 
 Non- vitamin K antagonist (VKA) anticoagulants (NOACs) are the preferred therapy 
for prevention of ischemic stroke based on phase 3 trials, but there is insufficient 
information on their efficacy and safety in daily practice, based on prospectively 
collected data    
 
WHAT IS NEW 
 This study shows that in non-valvular AF patient population, with up to 2 years of 
follow-up, the use of dabigatran led to a low incidence of ischemic stroke, major 
bleeding, and myocardial infarction in routine clinical care, confirming the sustained 
safety and effectiveness of dabigatran in clinical practice over 2 years of follow-up 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
1 
 
ABSTRACT 
  
Background and Purpose—GLORIA-AF is a large, global, prospective registry program of 
newly diagnosed atrial fibrillation (AF) patients with ≥1 stroke risk factors. We describe the 
effectiveness and safety of dabigatran etexilate over 2 years from routine clinical practice in 
nearly 3000 patients from GLORIA-AF who are newly diagnosed with non-valvular AF and 
at risk of stroke.  
Methods—Consecutive enrollment into phase II of GLORIA-AF was initiated following 
approval of dabigatran for stroke prevention in non-valvular AF. Within this Phase II, 2937 
dabigatran patients completed 2-year follow-up by May 2016 and were eligible for analysis. 
Patients who took at least 1 dose of dabigatran (n=2932) were used to estimate incidence 
rates.  
Results—Overall incidence rates per 100 person-years of 0.63 (95% confidence interval [CI], 
0.42–0.92) for stroke, 1.12 (0.83–1.49) for major bleeding, 0.47 (0.29–0.72) for myocardial 
infarction, and 2.69 (2.22–3.23) for all-cause death were observed. For patients taking 150 
mg dabigatran twice daily (BID), corresponding rates (95% CI) were 0.56 (0.30–0.94), 1.00 
(0.64–1.47), 0.48 (0.25–0.83), and 2.07 (1.55–2.72), respectively. For patients taking 110 mg 
dabigatran BID, event rates (95% CI) were 0.67 (0.33–1.20), 1.16 (0.70–1.80), 0.43 (0.17–
0.88), and 3.16 (2.36–4.15). 
Conclusions—These global data confirm the sustained safety and effectiveness of dabigatran 
over 2 years of follow-up, consistent with the results from clinical trials as well as 
contemporary real-world studies. 
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifiers: 
NCT01468701, NCT01671007, and NCT01937377. 
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Introduction 
Anticoagulant therapy is indicated to reduce the risk of ischemic stroke in patients with atrial 
fibrillation (AF). Vitamin K antagonists (VKAs; for example, warfarin) significantly reduce 
the risk of ischemic stroke and death but increase the risk of major bleeding and intracranial 
hemorrhage (ICH).
1
 Non-VKA oral anticoagulants (NOACs) have been shown to be at least 
as effective but safer than VKAs in terms of ICH
2
 and are now indicated as preferential 
anticoagulants in most recent guidelines.
3
 
 
While several non-interventional studies based on, for example, claims data or nationwide 
registries have been published showing the effectiveness and safety of dabigatran etexilate 
(hereafter “dabigatran”) compared with warfarin,4–8 prospective registries will provide 
complementary evidence of the effectiveness and safety of dabigatran in daily practice. 
 
The Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial 
Fibrillation (GLORIA-AF) registry program is a large, global, prospective registry of 
consecutive newly diagnosed AF patients with ≥1 stroke risk factor.9 Here, we report a pre-
specified interim analysis of 2937 dabigatran patients in phase II of GLORIA-AF who 
completed 2-year follow-up by May 2016.  
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Methods 
Design  
The design of GLORIA-AF, a global, non-interventional registry program with 3 phases, has 
been described in detail.
9
  In phase II, which started in each country upon approval of 
dabigatran, cross-sectional data, for example, AF disease characteristics, medical conditions 
including concomitant diseases, and medications, were collected at baseline for all enrolled 
patients with newly diagnosed AF. No additional procedures, apart from assessments 
performed as part of routine clinical practice, were required. In patients prescribed 
dabigatran, 2-year follow-up was performed to  describe its safety and effectiveness. Ethical 
approval was obtained from the Institutional Review Boards as required at participating sites.  
 
Patients 
Consecutive adult patients with ≥1 risk factor for stroke [CHA2DS2-VASc scores ≥1, based on 
the presence of congestive heart failure; hypertension; age ≥75 years (doubled); diabetes; stroke 
(doubled); vascular disease; age 65–74 years; and sex category (female)], and newly diagnosed 
with non-valvular AF (that is AF diagnosed within 3 months of the first visit [[documented by 
12-lead electrocardiogram (ECG), ECG rhythm strip, pacemaker/implantable cardioverter 
defibrillator ECG, or Holter ECG] were included between November 2011 and December 
2014. Patients with mechanical heart valves, prior VKA therapy for >60 days, life expectancy ≤ 
1 year at enrollment, a medical condition other than AF for which chronic use of VKAs is 
indicated and AF due to a generally reversible cause were excluded. Bleeding risk was assessed 
by the HAS-BLED bleeding score, which includes the presence of hypertension, abnormal 
renal and/or liver function, stroke, bleeding history or predisposition, labile international 
normalized ratio, age >65 years, and drugs and/or alcohol concomitantly.
10
 Patients were 
recruited from outpatient settings including university hospitals, community hospitals, 
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specialist offices, and general practice offices. Centers were selected to reflect physicians who 
typically identify and manage new AF cases in a given country.  
 
Medication 
Dabigatran was prescribed at the discretion of the treating physician, and according to 
available doses (150, 110, and 75 mg twice daily [BID] depending on the country and local 
label); patients who took at least 1 dose of dabigatran were included in the outcome event 
analysis.  
 
Follow-up and Outcomes 
Follow-up visits took place at 3, 6, 12, and 24 months post baseline. Two-year outcomes 
included stroke (ischemic or hemorrhagic), systemic embolism, major bleeding, life-
threatening bleeding, myocardial infarction (MI), vascular death, all-cause death (including 
death of unknown cause), as well as the composite end point of stroke, systemic embolism, 
MI, life-threatening bleeding, and vascular death. The analysis for estimation of incidence 
rates includes only the dabigatran treatment period as prespecified in the analysis plan.  Data 
collected after permanent discontinuation of dabigatran (defined as treatment discontinued for 
>30 days or switch to another OAC) were not included in the analysis.  
 
Data Collection and Quality Control 
Clinical data were collected using a validated web-based system to ensure confidentiality and 
integrity. Study staff at each site entered data over a secure network and study physicians 
electronically signed the case report form to confirm accuracy and completeness of the 
information. Data quality and queries were addressed during bimonthly telephone calls to all 
sites, by periodic site monitoring, and independent audits. Additional data quality measures 
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included automatic programmed data checks, bimonthly manual data reviews, and quarterly 
medical quality reviews of aggregate data to address any systematic data issues identified (for 
example, trends for missing data). 
 
Statistical Analysis 
Data are summarized by means or medians and standard deviation (SD) or quartiles (Q1, Q3) 
for continuous variables, and by frequencies and percentages for categorical variables. 
Incidence rates are shown per 100 person-years and two-sided 95% confidence intervals 
(CIs), based on the Poisson distribution and its relation to the χ2-distribution,11 and are based 
on the period from commencement of dabigatran until permanent treatment cessation (that is, 
treatment stop +3 days, switch to another treatment, or study completion/discontinuation). 
Treatment interruptions of <30 days were disregarded for the analyses. Kaplan-Meier plots 
for time-to-event data are provided. Descriptive results are presented and no statistical 
hypothesis tests were performed. Statistical analyses were performed using SAS software 
version 9.4 (SAS Institute Inc., Cary, NC, USA).  
 
 
 
Results 
Of 15 641 patients enrolled in 44 countries, 2937 were prescribed dabigatran and were 
eligible for this interim analysis of 2-year follow-up data; 2932 took dabigatran at least once 
and were included in the outcome analysis.   
 
Dabigatran was prescribed mostly by cardiologists (91.1%). Other treating physicians 
included general practitioners (3.5%), internists (2.1%), and neurologists (1.6%).  The 
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majority of patients were followed at a specialist office (36.4%), community hospital 
(29.5%), university hospital (21.7%), and the remainders were treated at a primary care 
center (7.7%), outpatient or anticoagulation clinics (4.0%), or “other” (0.8%). Participating 
countries per region and regional contributions are summarized in Figure 1. 
 
Mean age at enrollment was 70.3 years (SD, 10.2), median 71.0 (Q1–Q3, 64.0–78.0). Table 1 
shows patient demographic and baseline characteristics. The most prevalent comorbidities 
were history of hypertension (78.9%), hyperlipidemia (44.5%), congestive heart failure 
(24.9%), diabetes mellitus (22.7%), left ventricular hypertrophy (25.0%), coronary artery 
disease (20.2%), and history of stroke (10.1%). Paroxysmal AF was present in 50.6% of 
patients, 36.2% had persistent AF, and 13.2% had permanent AF. AF was symptomatic in 
26.5%, and minimally symptomatic or asymptomatic in 73.5% of patients. The median 
CHA2DS2-VASc score was 3.0 (SD, 1.4), and 88.2% had CHA2DS2-VASc score ≥2. Median 
HAS-BLED score was 1.0 (SD, 0.8), with scores <3 in most patients (83.5%). 
 
 Dabigatran Treatment 
Dabigatran 150 mg BID was prescribed to 1748 (59.5%), dabigatran 110 mg BID to 1106 
(37.7%), and dabigatran 75 mg BID to 73 (2.5%) patients. Mean duration of on-treatment 
follow-up in the initial treatment period was 17.7 months (SD, 9.3).  The  probability that of 
remaining on dabigatran therapy for at least 24 months was ~70% based on Kaplan-Meier 
estimates.   Among patients who discontinued dabigatran (n = 828, 28.2%), approximately one third 
stopped dabigatran primarily due to dyspepsia or other AEs or SAEs. The majority of respondents 
cited “other” reason(s) (without further details) as the primary reason for discontinuation (n = 495, 
59.8%).  As expected, patients taking lower doses of dabigatran were older and had lower 
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creatinine clearances, higher CHA2DS2-VASc and HAS-BLED scores, and more often a past 
stroke event or MI (Table 1). 
 
Clinical Outcomes  
During follow-up the incidence rate per 100 person-years for stroke was 0.63 (95% CI, 0.42–
0.92; Table 2), for major bleeding 1.12 (95% CI, 0.83–1.49), for life-threatening bleeding 
0.54 (95% CI, 0.34–0.81), and for fatal bleeding 0.12 (95% CI, 0.04–0.27). Incidence rates 
per 100 person-years for MI, overall death, and vascular death were 0.47 (95% CI, 0.29–
0.72), 2.69 (95% CI, 2.22–3.23), and 0.91 (95% CI, 0.65–1.25), respectively. The rate of the 
composite end point—stroke, systemic embolism, MI, life-threatening bleed, or vascular 
death—was 2.24 (95% CI, 1.81–2.73) per 100 person-years. Figure 2 shows the estimated 
cumulative probabilities based on the Kaplan-Meier estimates for major bleeding, stroke, and 
MI. 
 
Table 3 shows outcomes by subtype. Among strokes, most were ischemic. Primary 
hemorrhagic strokes occurred in only 0.07 cases per 100 patient-years. Only 10.7% of stroke 
events were classified as hemorrhagic strokes. Gastrointestinal was the most prevalent 
bleeding location (upper 29%, lower 31%, not further specified 6%). 
 
Clinical Outcome by Different Doses of Dabigatran 
For patients taking 150 mg dabigatran BID, incidence rates per 100 patient-years were 0.56 
(95% CI, 0.30–0.94) for stroke, 1.00 (95% CI, 0.64–1.47) for major bleeding, 0.48 (95% CI, 
0.25–0.83) for MI, and 2.07 (95% CI, 1.55–2.72) for all-cause death. For patients taking 110 
mg dabigatran BID, corresponding event rates were 0.67 (0.33–1.20) for stroke, 1.16 (0.70–
1.80) for major bleeding, 0.43 (0.17–0.88) for MI, and 3.16 (2.36–4.15) for all-cause death 
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(Table 4). Data on 75 mg dabigatran BID were not included in this analysis due to limited 
patient numbers. 
 
Discussion 
This is the first global prospective study to follow a large cohort of consecutive, newly 
diagnosed AF patients treated with dabigatran in daily clinical practice. After up to 2 years of  
follow-up the overall incidence rate for stroke (ischemic or hemorrhagic) was 0.63 per 100 
person-years (0.56 and 0.67 for patients taking dabigatran 150 and 110 mg BID, respectively) 
and for major bleeding was 1.12 per 100 person-years (1.16 for dabigatran 110 mg BID and 
1.00 for dabigatran 150 mg BID).  
 
Comparison With Other Non-Interventional Studies 
Direct comparisons with other published incidence rates are misleading unless adjusted for 
differences in patient characteristics. Standardizing the compared incidence rates addresses 
this problem
12
, but the data needed for standardization are seldom published. One exception 
was the US Food and Drug Administration (FDA)-sponsored Medicare claims database study 
(FDA/Medicare), which included patients aged ≥65 years taking dabigatran 150 or 75 mg 
BID and reported age- and sex-specific incidence rates.
4
 Consequently, we were able to 
standardize the results of this study to the age and sex distribution of GLORIA-AF for the 
population aged ≥65 years taking dabigatran 150 and 75 mg BID. In GLORIA-AF, for this 
specific population, incidence rates per 100 patient-years were 0.66 for ischemic stroke, 0.18 
for ICH, and 0.95 for major gastrointestinal bleeding. The corresponding incidence rates per 
100 patient-years in the FDA/Medicare study, standardized to the GLORIA-AF age and sex 
distribution, are 0.95, 0.26, and 2.66, respectively. Before standardization, the FDA/Medicare 
rates were 1.13, 0.33, and 3.42, respectively, which are higher because the age distribution of 
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the FDA/Medicare population was also higher. We emphasize that standardization by age and 
sex reduces bias in the comparison, but other differences in baseline characteristics (for 
example, stroke and bleeding risks) or study design (for example, duration of on-treatment 
follow-up, which was much shorter in the FDA/Medicare study) may remain.  
 
Other studies of incidence rates of outcomes for patients treated with dabigatran did not 
report data that would allow for standardization. The overall stroke (ischemic or 
hemorrhagic) incidence rate was 0.92 in a US Department of Defense claims database
7
 and 
0.77 in a combined analysis from 2 US health insurance databases (both studies including 
patients taking dabigatran 150 or 75 mg BID).
8
 The major bleeding rates were 3.08 and 4.42 
per 100 person-years, respectively.
7,8
 In a study performed in Danish registries, for VKA 
naïve patients, when considering outcomes occurring during dabigatran treatment, the major 
bleeding rates were 4.4 per 100 person-years for patients taking dabigatran 110 mg BID and 
2.3 per 100 person-years for patients taking dabigatran 150 mg BID.
5
  
 
Stroke and bleeding risks varied across studies: 72% of patients had a CHADS2 score of ≥2.0 
in the FDA/Medicare analysis (the mean score was not reported).
4 
The proportion of 
GLORIA-AF patients with a history of stroke (10%) was also higher than in the 
FDA/Medicare study (3%). In the US database analysis, the CHA2DS2-VASc score (3.9) was 
higher than in GLORIA-AF,
7
 whereas Seeger et al reported a slightly lower CHA2DS2-VASc 
score (2.8) and similar CHADS2 score (1.9).
8
 Mean HAS-BLED scores were not reported for 
most of these database analyses, but the proportion of patients with low HAS-BLED score 
(<3) was higher in GLORIA-AF (83%) than in the FDA/Medicare analysis (59%),
4
 the 
pooled commercial health insurance databases analysis (65%),
8
 and the Department of 
Defense analysis (23%).
7
 In the Danish registry study, the mean HAS-BLED scores of the 
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VKA naïve patients were 2.32 and 1.70 for patients taking dabigatran 110 and 150 mg BID, 
respectively, compared with 1.4 and 1.1 in GLORIA-AF. In a routine clinical practice setting, 
one prospective study evaluating rivaroxaban found comparable stroke rates of 0.7 (95% CI, 
0.5–0.9) per 100 person-years but somewhat higher major bleeding rates of 2.1 (1.8–2.5) per 
100 person-years.
13
 Although the mean HAS-BLED scores were not reported, the mean 
CHA2DS2-VASc score (3.4; SD, 1.7) was similar to that in GLORIA-AF.  
 
In the Context of Clinical Trial Data (RE-LY
®
) 
In the RE-LY
®
 trial, stroke incidence rates per 100 person-years were 1.01 and 1.44 for 
dabigatran 150 and 110 mg BID, respectively.
14
 The corresponding figures for major 
bleeding were 3.11 and 2.71 per 100 person-years.
14 
Event rates in RE-LY, however, should 
not be compared with the present findings because of differences in the study design, study 
populations, and stroke and bleeding risk profiles of patients; for example, GLORIA-AF was 
conducted in a newly diagnosed AF population while the RE-LY
14
 study was not. In addition, 
the baseline CHA2DS2-VASc score in GLORIA-AF was 3.2 and the mean CHADS2 score 
was 1.9, whereas in the RE-LY study
14
 the mean CHADS2 score was 2.1. The proportion of 
GLORIA-AF patients with a history of stroke (10%) was lower than in the RE-LY study 
(20%). Moreover, the mean HAS-BLED score was relatively low in GLORIA-AF, which 
may partly explain the low major bleeding rates. Finally, in GLORIA-AF, the dose selection 
was determined by physician choice, while in the RE-LY
14
 trial, dose selection was 
undertaken by randomization.  
 
The fact that in GLORIA-AF the dabigatran dosages are prescribed by physician choice and 
stroke and bleeding rates of both examined dabigatran dosages were low is reassuring and 
underlines the safety of dabigatran in clinical practice.    
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Persistence 
One important potential advantage of NOAC use is persistence on therapy. After 2 years of 
follow-up, approximately 70% of AF patients were still taking dabigatran, which compares 
favorably with reported persistence on warfarin, which in one study was only 45% at 1 
year.
15
 In the prospective study with once-daily rivaroxaban, the therapy persistence rate in 
clinical practice after 1 year was 80% (data after 2 years are not available), similar that 
observed in GLORIA-AF with the BID dabigatran regimen (77% after 1 year), indicating that 
once- or twice-daily dosing of a NOAC seems not to impact therapy persistence.
13
  
 
Limitations and Strengths  
Phase II of the GLORIA-AF registry program involved follow-up of dabigatran-treated 
patients. Consequently, no direct comparisons can be made with other anticoagulants. 
However, data can be put into perspective by using recent results from other non-
interventional and interventional studies. In the ongoing phase III of GLORIA-AF, follow-up 
data will be collected from all patients, allowing safety and effectiveness analysis for other 
oral anticoagulants also in a global prospective cohort.
9
 No direct comparisons can be made 
between the dabigatran 150 and 110 mg BID doses since the patient populations differ and, 
because of the sample size and low numbers of events, only crude incidence rates are 
provided here. In addition, the outcomes have not been adjudicated in this routine clinical 
practice analysis. Our cohort had a low HAS-BLED score, which may have led to low major 
bleeding rates. Moreover, this interim cohort predominantly contained patients from Europe 
(51%) and North America (28%), making it difficult to draw conclusions for other regions 
(Latin America, Africa and the Middle East, and Asia). Nonetheless, this study is the largest 
prospective global cohort of consecutive dabigatran-treated patients reported thus far. 
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Additional strengths include the regular bimonthly follow-up with physicians to ensure event 
capture, with regular on-site monitoring and quality reviewing, and the broad physician and 
site selection worldwide. 
 
Conclusions 
This large, global, prospective, observational analysis describing the use of dabigatran in a 
broad, non-valvular AF patient population with up to 2 years of follow-up showed a low 
incidence of ischemic stroke, major bleeding, and MI when used in routine clinical care. 
These data confirm the sustained safety and effectiveness of dabigatran in clinical practice 
over 2 years of follow-up, consistent with the results observed in clinical trials as well as in 
contemporary real-world analyses. 
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Figure Legends 
Figure 1. Patients per region  
A total of 15 092 patients from 44 countries were analyzed in GLORIA-AF 
phase II (November 2011 to December 2014); 2937 patients were prescribed 
dabigatran and completed 2-year follow-up before February 2016 
Figure 2. Kaplan-Meier curves for stroke, major bleeding, and myocardial infarction in 
dabigatran-treated patients overall (N=2932 eligible patients)  
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Table 1. Patient Demographics and Baseline Characteristics by Dabigatran Dose Group* 
 Dabigatran 
150 mg BID 
(N=1748) 
Dabigatran 
110 mg BID 
(N=1106) 
Dabigatran 
75 mg BID 
(N=73) 
Dabigatran 
overall 
(N=2937) 
Age, mean (SD), years 67.2 (9.6) 74.6 (9.3) 78.7 (8.7) 70.3 (10.2) 
Age class 1, n (%)     
<80 y 1597 (91.4) 734 (66.4) 34 (46.6) 2372 (80.8) 
≥80 y 151 (8.6) 372 (33.6) 39 (53.4) 565 (19.2) 
Age class 2, n (%)     
<65 y 628 (35.9) 155 (14.0) 5 (6.8) 790 (26.9) 
65–<75 y 737 (42.2) 316 (28.6) 13 (17.8) 1070 (36.4) 
≥75 y 383 (21.9) 635 (57.4) 55 (75.3) 1077 (36.7) 
BMI, mean (SD), kg/m
2
 30.3 (6.4) 27.5 (5.0) 28.4 (8.7) 29.2 (6.1) 
Sex, male, n (%) 1049 (60.0) 544 (49.2) 27 (37.0) 1623 (55.3) 
Type of AF, n (%)     
Paroxysmal 917 (52.5) 523 (47.3) 37 (50.7) 1486 (50.6) 
Persistent 660 (37.8) 369 (33.4) 34 (46.6) 1063 (36.2) 
Permanent 171 (9.8) 214 (19.3) 2 (2.7) 388 (13.2) 
Categorization of AF, n (%)     
Symptomatic 480 (27.5) 277 (25.0) 19 (26.0) 779 (26.5) 
Minimally symptomatic 784 (44.9) 537 (48.6) 37 (50.7) 1365 (46.5) 
Asymptomatic 484 (27.7) 292 (26.4) 17 (23.3) 793 (27.0) 
Medical history, n (%)     
Previous stroke 149 (8.5) 140 (12.7) 5 (6.8) 296 (10.1) 
MI 120 (6.9) 118 (10.7) 10 (13.7) 248 (8.4) 
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Coronary artery disease 316 (18.1) 247 (22.3) 28 (38.4) 592 (20.2) 
Congestive heart failure 398 (22.8) 312 (28.2) 19 (26.0) 732 (24.9) 
History of hypertension 1394 (79.7) 846 (76.5) 69 (94.5) 2317 (78.9) 
Diabetes mellitus 416 (23.8) 220 (19.9) 26 (35.6) 666 (22.7) 
Hyperlipidemia 823 (47.1) 433 (39.2) 45 (61.6) 1307 (44.5) 
Prior bleeding 80 (4.6) 63 (5.7) 4 (5.5) 147 (5.0) 
Renal impairment†, n (%) 4 (0.2) 3 (0.3) 5 (6.8) 12 (0.4) 
Creatinine clearance, mean, 
mL/min 
93.9 (37.3) 68.4 (26.6) 57.6 (34.0) 83.2 (35.9) 
CHA2DS2-VASc score, mean 
(SD) 
2.9 (1.3) 3.7 (1.4) 4.4 (1.4) 3.2 (1.4) 
CHA2DS2-VASc score, n 
(%) 
    
Score=1 274 (15.7)– 70 (6.3)– 1 (1.4)– 346 (11.8) 
Score ≥2  1474 (84.3)– 1036 (93.7)– 72 (98.6)– 2591 (88.2) 
CHADS2 score, mean (SD) 1.7 (1.0) 2.2 (1.1) 2.6 (1.1) 1.9 (1.1) 
CHADS2 score category, n 
(%) 
  
 
 
Low, score=0 124 (7.1) 51 (4.6) 0 (0.0)– 175 (6.0) 
Moderate, score=1 719 (41.1)– 284 (25.7)– 11 (15.1)– 1019 (34.7) 
High, score ≥2  904 (51.7)– 771 (69.7)– 62 (84.9)– 1742 (59.3) 
Missing 1 (0.1)– 0 (0.0)– 0 (0.0)– 1 (0.0) 
HAS-BLED score, mean (SD) 1.1 (0.9) 1.4 (0.8) 1.6 (0.9) 1.2 (0.8) 
HAS-BLED score category, 
n (%) 
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Low, score <3 1448 (82.8)– 939 (84.9)– 57 (78.1)– 2452 (83.5) 
High, score ≥3 101 (5.8)– 70 (6.3)– 11 (15.1)– 184 (6.3) 
Missing 199 (11.4)– 97 (8.8)– 5 (6.8)– 301 (10.2) 
 
AF, atrial fibrillation; BID, twice daily; BMI, body mass index; CHA2DS2-VASc, congestive 
heart failure, hypertension, age ≥75 years (doubled), diabetes, stroke (doubled), vascular 
disease, age 65–74 years, and sex category (female); CHADS2, congestive heart failure, 
hypertension, age (>65 years =1 point, >75 years =2 points), diabetes, and stroke/transient 
ischemic attack (=2 points); HAS-BLED, hypertension, abnormal renal and/or liver function, 
stroke, bleeding history or predisposition, labile international normalized ratio, elderly (65 
years), drugs and/or alcohol concomitantly; MI, myocardial infarction; SD, standard 
deviation. 
*10 patients with other dosages of dabigatran are included in “Dabigatran overall” but not in 
the other columns in this table. 
†Defined as chronic dialysis, renal transplantation, serum creatinine >200 μmol/L (2.26 
mg/dL) in case report forms.
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Table 2. Incidence of Events in Dabigatran-Treated Patients Overall 
 Patients 
With 
Event,* n 
Person- 
Years 
Incidence 
Rate Per 100 
Person-Years 
95% CI 
Stroke (ischemic or hemorrhagic) 27 4261 0.63 0.42–0.92 
Systemic embolism 2 4274 0.05 0.01–0.17 
Major bleeding 48 4267 1.12 0.83–1.49 
Life-threatening bleeding 23 4275 0.54 0.34–0.81 
Myocardial infarction 20 4270 0.47 0.29–0.72 
Vascular death 39 4277 0.91 0.65–1.25 
All-cause death† 115 4277 2.69 2.22–3.23 
Composite end point‡ 95 4249 2.24 1.81–2.73 
 
CI, confidence interval; MI, myocardial infarction. 
*In the case of a recurrent event, the first event was considered. 
†Including cause of death unknown, n=36 (31.3%). 
‡Stroke, systemic embolism, MI, life-threatening bleeding, vascular death. N=2932 eligible 
patients. 
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Table 3. Incidence of Events by Type or Location in Dabigatran-Treated Patients Overall 
  Incidence Rate Per  
100 Person-Years 
95% CI 
Stroke 0.63 0.42–0.92 
Hemorrhagic stroke 0.07 0.01–0.20 
Ischemic stroke 0.45 0.27–0.70 
Secondary hemorrhagic transformation 0.05 0.01–0.17 
Unknown type/uncertain classification 0.12 0.04–0.27 
Major bleeding 1.12 0.83–1.49 
Life-threatening bleed 0.54 0.34–0.81 
Led to transfusion of ≥2 units of blood/red cells  0.68 0.45–0.98 
Fall in hemoglobin level of 2 g/dL 0.63 0.42–0.92 
Fatal bleeds 0.12 0.04–0.27 
Trauma involved 0.07 0.01–0.20 
Location of bleed   
Intracranial 0.19 0.08–0.37 
Gastrointestinal 0.73 0.49–1.03 
Other 0.16 0.07–0.34 
Unknown 0.05 0.01–0.17 
All-cause death 2.69 2.22–3.23 
Vascular death 0.91 0.65–1.25 
Non-vascular death 0.94 0.67–1.27 
Unknown 0.84 0.59–1.17 
CI, confidence interval. 
N=2932 eligible patients. 
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Table 4. Incidence of Events by Dabigatran Dose Group 
 Patients 
With 
Event*, 
n 
Patient-
Years 
Incidence Rate 
Per 100  
Person-years 
95% CI 
Dabigatran 150 mg BID (n=1747)  
Stroke (ischemic or hemorrhagic) 14 2521 0.56 0.30–0.94 
Major bleeding 25 2526 1.00 0.64–1.47 
MI 12 2528 0.48 0.25–0.83 
All-cause death 52 2532 2.07 1.55–2.72 
Dabigatran 110 mg BID (n=1105) 
Stroke (ischemic or hemorrhagic) 11 1654 0.67 0.33–1.20 
Major bleeding 19 1656 1.16 0.70–1.80 
MI 7 1656 0.43 0.17–0.88 
All-cause death 52 1659 3.16 2.36–4.15 
BID, twice daily; CI, confidence interval; MI, myocardial infarction. 
*In the case of a recurrent event, the first event was considered.
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Figure 1. 
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Figure 2.  
 
